Introduction {#s1}
============

Nontyphoidal *Salmonella* serovars (NTS) have been a prominent cause of potentially fatal bacteraemia in Malawi and elsewhere in sub-Saharan Africa for more than fifteen years [@pone.0042085-Sow1], [@pone.0042085-Feasey1], [@pone.0042085-Kariuki1], [@pone.0042085-Graham1]. The majority of isolates in this epidemic are multidrug resistant (MDR) (ampicillin, chloramphenicol and cotrimoxazole), leaving limited therapeutic options for case management [@pone.0042085-Gordon1], [@pone.0042085-Kariuki2]. Reports of ceftriaxone and ciprofloxacin resistant *Salmonella* Typhimurium are now emerging from South Africa, emphasising the paramount importance of developing appropriate public health prevention strategies [@pone.0042085-Usha1]. A vaccine approach to the prevention of NTS bacteraemia will require both an improved understanding of the mechanisms of protective immunity [@pone.0042085-Gondwe1], [@pone.0042085-MacLennan1], [@pone.0042085-MacLennan2], [@pone.0042085-Nyirenda1] and of the genetic diversity of the circulating invasive strains [@pone.0042085-Clemens1].

In sub-Saharan Africa, invasive NTS particularly affects young children, frequently in association with malnutrition, malaria, severe anaemia and/or HIV infection; and adults almost exclusively with marked HIV-associated immunosuppression [@pone.0042085-Graham1], [@pone.0042085-Brent1], [@pone.0042085-Gordon2]. Acquisition of *Salmonella* antibody in children is thought to be protective against bacteraemia [@pone.0042085-MacLennan2], while in HIV-infected adults there appears to be dysregulated humoral immunity due to production of antibodies that block bactericidal killing of NTS [@pone.0042085-MacLennan1], and dysregulated cellular immunity [@pone.0042085-Gordon3], [@pone.0042085-Gordon4], [@pone.0042085-Schreiber1]

Until recently, our understanding of the diversity of *Salmonella* strains causing bacteraemia in children and HIV-infected adults in Malawi was based on serovar and antibiotic resistance differences [@pone.0042085-Gordon1]. We have recently determined that the *S*. Typhimurium strains in Malawi and Kenya belong to sequence type ST313, which is rarely isolated outside sub-Saharan Africa. Whole genome sequencing of epidemic ST313 strains identified a distinct prophage repertoire and a composite element encoding MDR genes located on a virulence-associated plasmid (pSLT-BT, EMBL accession number FN432031) [@pone.0042085-Kingsley1]. Evidence of genome degradation, including pseudogene formation and chromosomal deletions found in these strains, suggests that these *S*. Typhimurium strains may have become human adapted [@pone.0042085-Sakharkar1], [@pone.0042085-Moran1], [@pone.0042085-Chain1]. Similar genomic degradation has been identified in host-restricted *Salmonella* serovars such as *S*. Typhi, *S*. Paratyphi A and *S*. Gallinarum [@pone.0042085-Holt1], [@pone.0042085-Thomson1], [@pone.0042085-Parkhill1].

Experimental studies with *E. coli* raise the possibility that the environment within a host can personalise infecting pathogens [@pone.0042085-Zdziarski1], [@pone.0042085-Gordon5], [@pone.0042085-Sokurenko1], [@pone.0042085-Alizon1]. A recent study of recurrent invasive ST313 *S*. Typhimurium disease in HIV-infected Malawian adults has, however, shown no evidence of within-individual microevolution across multiple episodes of recurrent disease over time [@pone.0042085-Okoro1]. In view of the distinct at-risk populations for invasive NTS in sub-Saharan Africa and the potential impact on prevention strategies, we have investigated the hypothesis that host differences imprint on the genotype of ST313 MDR *S*. Typhimurium isolates from HIV-infected adults and children and from HIV-uninfected children.

Results {#s2}
=======

*Salmonella* Typhimurium isolates that underwent Illumina sequencing comprised representative isolates from HIV-infected adults, HIV-infected children and HIV-uninfected children, from two periods; 2002/2003 and 2006/2008. All 27 isolates from both time periods clustered with the MDR epidemic strain D23580 ([Figure 1](#pone-0042085-g001){ref-type="fig"}). Isolates from patients with the same HIV-status or age were no more related to each other than isolates from other susceptibility groups ([Figure 2](#pone-0042085-g002){ref-type="fig"}).

![A rectangular phylogram depicting the relatedness of *S*. Typhimurium strains.\
Phylogeny of invasive multidrug resistant *S*. Typhimurium strains isolated from HIV-infected adults (A+) and children (C+) and HIV-uninfected children (C−) in Blantyre, Malawi, from the period 2002 to 2008 including the epidemic strain D23580. The phylogram also includes the reference gastroenteritis strain SL1344 and the invasive, chloramphenicol-susceptible, pre-epidemic strain A130 as outgroups. A clade consisting isolates from 2006 and 2008 only is highlighted in red. The scale bar value 0.2 represents expected substitutions per site.](pone.0042085.g001){#pone-0042085-g001}

![Lack of host specificity and microevolution.\
A subtree of the phylogram in [figure 1](#pone-0042085-g001){ref-type="fig"} depicting relatedness of invasive multidrug resistant *S*. Typhimurium strains from HIV-infected adults (A+) and children (C+) and HIV-uninfected children (C−) over time (2002--2008) including the epidemic strain D23580. The pre-epidemic chloramphenicol-susceptible *S*. Typhimurium strain A130 is included as an outgroup. The scale bar value 0.08 represents expected substitutions per site.](pone.0042085.g002){#pone-0042085-g002}

There was however distinct clustering within the D23580 clade based on year of isolation. A cluster of seven isolates contained exclusively isolates from 2006/2008. This small cluster was separated by 22 SNPs from the main group of 20 isolates and contained isolates from each of the three susceptibility groups; two from HIV-infected adults, one strain from an HIV-infected child and four from HIV-uninfected children ([Figure 2](#pone-0042085-g002){ref-type="fig"}). The topology of the tree indicates that the small cluster containing some of the most recent isolates shares a common ancestor with the larger cluster at the root of the tree, and does not branch off from within the large cluster containing other recent and all the older isolates. The maximum SNP distance within the main group of 20 isolates was fifteen to a 2008 blood isolate A50063. The tree pattern suggests limited accumulation of SNPs over time in the sampled *S*. Typhimurium.

In order to determine whether isolates from distinct susceptibility groups or dates of isolation had distinct genome features we carried out *de novo* assembly of short read sequence and ordered the contiguous sequence using the *S*. Typhimurium D23580 genome sequence and plasmid pSLT-BT from *S.* Typhimurium D23580. All 27 draft genomes were assembled and compared using SNPsFinder [@pone.0042085-Song1] and Artemis comparison tool (ACT) [@pone.0042085-Carver1]. Three SNPs located within intergenic space/noncoding regions, 12 non-synonymous and 2 synonymous SNPs distinguished the 2006/2008 subgroup of strains from the large cluster that includes D23580 ([Table 1](#pone-0042085-t001){ref-type="table"}). Differences between the populations include amino acid substitutions in an arginine exporter protein and in enzymes pyruvate dehydrogenase, fumarate hydratase and nitrate reductase ([Table 1](#pone-0042085-t001){ref-type="table"}). Arginine is essential in the induction of inducible nitric oxide synthase (iNOS) but also promotes the growth of bacterial pathogens [@pone.0042085-Nicholson1], [@pone.0042085-Das1]. Nitrate reductase contributes to the intracellular survival of *Salmonella*. Pyruvate dehydrogenase and fumarate hydratase are important in the production of energy for the bacterial cell activities [@pone.0042085-Sohaskey1], [@pone.0042085-Pei1]. There was no evidence of further genome degradation in the seemingly diverging sub-population except for one non-sense mutation in an open reading frame coding for xylanase/chitin deacetylase ([Table 1](#pone-0042085-t001){ref-type="table"}).

10.1371/journal.pone.0042085.t001

###### Single nucleotide polymorphisms unique to strains in the 2006/2008 clade.

![](pone.0042085.t001){#pone-0042085-t001-1}

  STM_MAL    STM                        Description                       LT2   D23580+19 other strains   2006/2008 strains   Amino acid    gene
  --------- ------ ----------------------------------------------------- ----- ------------------------- ------------------- ------------ --------
  4573       179                xylanase/chitin deacetylase                G               G                      A            Trp→stop    *yadE*
  39         285                  inner membrane protein                   G               G                      A            Ala→Thr       \-
  624        762                    fumarate hydratase                     G               G                      T            Leu→Ile       \-
  756        935                  pyruvate dehydrogenase                   C               T                      C            His→Arg     *poxB*
  1383       1578            nitrate reductase 2 beta subunit              C               C                      T            Arg→Cys     *narY*
  1403       1598                   regulatory protein                     G               A                      G           No change      \-
  2016       2150                 outer membrane protein                   A               A                      T            Asn→Lys     *yehB*
  2136       2277   ribonucleotide-diphosphate reductase subunit alpha     T               T                      C            Val→Ala     *nrdA*
  2170       2312                  hypothetical protein                    C               T                      C            Ile→Val       \-
                    intergenic space or other non-protein-coding region    G               A                      G               \-         \-
                    intergenic space or other non-protein-coding region    T               T                      A               \-         \-
  2847       3046                        hemolysin                         T               T                      C           No change    *yqfA*
  2865       3066                arginine exporter protein                 C               T                      C            Glu→Gly     *yggA*
                    intergenic space or other non-protein-coding region    A               A                      G               \-         \-
  3337       3509                  carboxylesterase BioH                   A               A                      C            Trp→Gly     *bioH*
  3719       3899                 ATP-dependent protease                   G               G                      A            Val→Ala     *yifB*
  4596       202         glutamate-1-semialdehyde aminotransferase         T               T                      C            Asn→Ser     *hemI*

Single nucleotide polymorphisms relative to *S*. Typhimurium strains LT2 and D23580, distinguishing the seven strains of the 2006/2008 lineage from the large cluster of MDR strains (19) and the corresponding amino acid changes. STM and STM_Mal are systematic identification for coding sequences in LT2 and D23580.

Trp -- tryptophan, Gln -- glutamine, Arg -- arginine, Ala -- alanine, Thr -- threonine, Leu -- leucine, Ile -- isoleucine, His -- histidine, Cys -- cysteine, Asn -- asparagine, Gly -- glycine.

The multidrug resistance locus encoded within a Tn*21*-like element on plasmid pSLT-BT from strains in the 2006/2008 subgroup is similar to the integron earlier characterised in *S*. Typhimurium D23580. Sequence reads of all 27 genomes were mapped to the sequence of the 117 kb plasmid pSLT-BT. Average percent coverage of plasmid pSLT-BT was 95% excluding sequence reads from one strain with a low percent coverage of 12% ([Table S1](#pone.0042085.s002){ref-type="supplementary-material"}). Assembled plasmid sequences showed that 5% of the genome that was not mapped is probably due to repeat regions within the Tn*21*-like element where sequence gaps exist. Mapping of sequence reads to pSLT-BT generated two SNP loci distributed between two isolates, D36435 from the 2006/2008 subgroup and D36807 from the large cluster of 20 isolates. The two SNPs lie within a putative resolvase coding sequence flanking multidrug resistance loci in both strains. Comparison of assembled plasmid sequences from the 2006/2008 subgroup to pSLT-BT using ACT demonstrated colinearity and synteny ([Figure S1](#pone.0042085.s001){ref-type="supplementary-material"}).

Discussion {#s3}
==========

We addressed the hypothesis that the genotypic composition of populations of multidrug resistant *S*. Typhimurium strains in Malawi will be influenced by factors which are responsible for the host\'s susceptibility to invasive NTS infection -- the principal factors being HIV infection and young age. Phylogenetic analysis revealed a high degree of genetic relatedness of MDR isolates ([Figure 2](#pone-0042085-g002){ref-type="fig"}). Clustering of *S*. Typhimurium strains in the phylogenetic tree did not show host preference between HIV-uninfected children and HIV-infected adults. It appears therefore that these strains have not undergone selection or adaptation to the different susceptible host groups. Selection pressures in the affected children and HIV-infected adults may be similar. Adaptive mutations have been identified in experimental models where mutations in *E. coli* isolates passaged through human volunteers could be identified with a particular infected host [@pone.0042085-Zdziarski1]. This was not the case in our different NTS affected groups. The absence of genotypes associated with a susceptible group does not entirely rule out the possibility of phenotypic adaptation of *S*. Typhimurium strains to the different hosts. Maestroni et al have recently demonstrated regulation of fitness genes in *S.* Typhimurium which enhance virulence after passage through mice without any apparent mutations [@pone.0042085-Mastroeni1]. It is possible that over a longer period of time such adaptations to different human hosts will emerge.

The high level of genetic relatedness among *S*. Typhimurium isolates from children and HIV-infected adults has implications for strategies to determine the source and mode of transmission and for development of interventions such as a vaccine. MDR *S*. Typhimurium in Malawi account for 90% of all NTS bacteraemia isolates but the source and modes of transmission have not being identified. Our findings suggest that both children and HIV-infected adults are infected by strains emanating from similar sources. Previous studies in Kenya and the Gambia have suggested that human-to-human transmission occurs in invasive NTS disease, since similar isolates could not be found in zoonotic and environmental sources [@pone.0042085-Dione1], [@pone.0042085-Kariuki3]. A majority of the strains in the phylogenetic tree clustered with the fully sequenced and annotated invasive *S*. Typhimurium strain D23580. We have previously shown a reduced genome in D23580 in comparison to gastroenteritis strains, a finding consistent with what we might expect of strains undergoing host adaptation. If *S*. Typhimurium strains in Malawi are circulating between HIV-infected adults and children, it will be important to determine which one of the susceptible groups is the main reservoir.

Multidrug resistant *S*. Typhimurium strains and other NTS serovars are not limited to Malawi; they are spread across sub-Saharan Africa [@pone.0042085-Sow1], [@pone.0042085-Kariuki1], [@pone.0042085-Gordon1], [@pone.0042085-Usha1]. Understanding the genetic diversity of these strains is key to developing a much needed vaccine as there are limited antibiotic choices against NTS infections. We have found that *S.* Typhimurium strains causing infection in adults and children are genetically similar suggesting that suitable antigenic targets for a vaccine providing protection to both children and HIV-infected adults might be identified. This type of study must be expanded to characterise diversity of other serovar populations in Malawi including *S*. Enteritidis -- the second most common NTS bacteraemia isolate -- and serovars in other parts of sub-Saharan Africa to ensure adequate coverage by candidate vaccines.

We have determined that 7/27 closely related strains of *S.* Typhimurium from the more recent period between 2006 and 2008 formed a separate clade suggesting a complex epidemiology involving microevolution over time. This divergence has some similarities to the epidemic increase of multidrug resistant *S*. Typhimurium strains between 2001 and 2002 [@pone.0042085-Gordon1] but the 2006/2008 divergent strains are closely related to the predominant type strain. The seemingly diverging subcluster of strains could be a reflection of much wider genetic variation that has not been fully captured in the characterised sample size in this study. The longest SNP distance within the large cluster of strains is 15 SNPs to a tip with a single isolate from 2008. This genetic distance is seven SNPs less than the distance distinguishing the 2006/2008 group of seven strains. Therefore it will be necessary to investigate a larger sample size than the present 27 strains to ascertain further the level of genetic diversity in the population of multidrug resistant *S*. Typhimurium in Malawi. Single nucleotide polymorphisms that distinguish the 2006/2008 sub-population ([Table 1](#pone-0042085-t001){ref-type="table"}) include regions that previously have been shown to impact anaerobic intracellular growth of bacteria. Paiva et al have demonstrated that mutations in nitrate reductase and fumarate reductase genes attenuate the intracellular growth of *Salmonella* Gallinarum in chickens [@pone.0042085-Paiva1]. Further investigations to understand what these single nucleotide polymorphisms mean to the clinical presentation in both HIV-infected adults and children, and to the epidemiology of *S*. Typhimurium strains over time are warranted. It will also be important to determine the selection pressures driving these changes.

In conclusion we have demonstrated the genotypic homogeneity of MDR *S*. Typhimurium strains isolated from HIV-infected adults and children and from HIV-uninfected children, indicating that similar strains are circulating between the distinct susceptibility groups. Homogeneity of the strains suggests that adults and children may have the same sources of infection. We have shown that microevolution of MDR *S*. Typhimurium strains has occurred in Malawi within the past decade. Molecular tools are now available to study the biology of these pathogens and to explore mechanisms that influence clinical presentation and epidemiology.

Materials and Methods {#s4}
=====================

Bacterial Isolates {#s4a}
------------------

We investigated 27 invasive multidrug resistant *S*. Typhimurium strains isolated from blood or cerebrospinal fluid during the period 2002 to 2008 ([Table 2](#pone-0042085-t002){ref-type="table"}). As described previously, these isolates were obtained as part of routine surveillance for invasive bacterial infection amongst children and adults presenting with a febrile illness to Queen Elizabeth Central Hospital (QECH), Blantyre Malawi [@pone.0042085-Gordon1]. Bacterial strains were selected randomly from 234 *S*. Typhimurium isolated from blood or cerebrospinal fluid of children and adults who participated in three studies in 2002, 2006 and 2008 at QECH and their HIV-sero status was known. Twenty-one strains were from 10/65 HIV-infected and 11/72 HIV-uninfected children. Six strains were selected from a group of 97 isolates from HIV-infected adults. Bacterial culture and antibiotic sensitivity testing were carried out using standard previously described protocols [@pone.0042085-Gordon1].

10.1371/journal.pone.0042085.t002

###### List of sequenced invasive MDR *S*. Typhimurium strains (2002--2008).

![](pone.0042085.t002){#pone-0042085-t002-2}

  Isolate    Year   Sero status                  source                  sex   CN   CRO   C   AMP   SXT   CIP
  --------- ------ ------------- -------------------------------------- ----- ---- ----- --- ----- ----- -----
  D15132     2002      HIV−                      blood                    F    S     S    R    R     R     S
  D15176     2002      HIV−                      blood                    M    S     S    R    R     R     S
  D15759     2002      HIV−                      blood                    F    S     S    R    R     R     S
  C5158      2002      HIV−       CSF[\*](#nt104){ref-type="table-fn"}    M    S     S    R    R     R     S
  C5371      2002      HIV−       CSF[\*](#nt104){ref-type="table-fn"}    M    S     S    R    R     R     S
  D15330     2002      HIV+                      blood                    F    S     S    R    R     R     S
  D16287     2002      HIV+                      blood                    F    S     S    R    R     R     S
  A16802     2002      HIV+                      blood                    F    S     S    R    R     R     S
  D18791     2003      HIV+                      blood                    M    S     S    R    R     R     S
  D19828     2003      HIV+                      blood                    M    S     S    R    R     R     S
  A19741     2003      HIV+                      blood                    F    S     S    R    R     R     S
  A22804     2003      HIV+                      blood                    M    S     S    R    R     R     S
  D36225     2006      HIV+                      blood                    F    S     S    R    R     R     S
  D36099     2006      HIV+                      blood                    M    S     S    R    R     R     S
  D36435     2006      HIV+                      blood                    F    S     S    R    R     R     S
  D36457     2006      HIV+                      blood                    M    S     S    R    R     R     S
  D36807     2006      HIV+                      blood                    M    S     S    R    R     R     S
  D37381     2006      HIV+                      blood                    M    S     S    R    R     R     S
  D36233     2006      HIV−                      blood                    F    S     S    R    R     R     S
  D36448     2006      HIV−                      blood                    F    S     S    R    R     R     S
  D36632     2006      HIV−                      blood                    F    S     S    R    R     R     S
  D37712     2006      HIV−                      blood                    F    S     S    R    R     R     S
  D37905     2006      HIV−                      blood                    M    S     S    R    R     R     S
  D37601     2006      HIV−                      blood                    F    S     S    R    R     R     S
  A50063     2008      HIV+                      blood                    M    S     S    R    R     R     S
  A50070     2008      HIV+                      blood                    M    S     S    R    R     R     S
  A50315     2008      HIV+                      blood                    M    S     S    R    R     R     S

Invasive multidrug resistant *S*. Typhimurium strains from Malawian adults and children and corresponding resistance profiles. (CN = gentamicin, CRO = ceftriaxone, C = chloramphenicol, Amp = ampicillin, SXT = cotrimoxazole, CIP = ciprofloxacin).

CSF = cerebrospinal fluid.

DNA preparation and Sequence alignment {#s4b}
--------------------------------------

Genomic DNA was extracted using the Wizard Genome DNA purification kit (Promega, USA) according to the manufacturer\'s instructions. Genomic DNA sequencing was carried out using the Illumina GA platform (Illumina, UK) in groups of 12 index tagged pools in 54 cycle runs at the Wellcome Trust Sanger Institute, UK. Sequence reads were mapped to plasmid pSLT-BT sequence and to the gastroenteritis *S.* Typhimurium strain SL1344 [@pone.0042085-Hoiseth1] genome sequence excluding highly variable prophage elements. Prophage elements and repeat sites constituting ∼7% of the reference SL1344 genome were excluded using repeatfinding programmes nucmer, REPeuter and repeat-match [@pone.0042085-Holt2], [@pone.0042085-He1], [@pone.0042085-Kurtz1], [@pone.0042085-Kurtz2]. Reads were mapped using the Burrows-Wheeler Aligner software (BWA) with a minimum read depth of 4 [@pone.0042085-Li1]. SNPs were identified using mpileup and samtools and filtered with a minimum mapping quality to call a SNP of 30 and a SNP/mapping quality ratio cut-off of 0.75 [@pone.0042085-Okoro1], [@pone.0042085-Li2], [@pone.0042085-Harris1]. A total of 1159 single nucleotide polymorphisms (SNP) sites were identified across the chromosome with an average percent coverage of 94% of the SL1344 sequence ([Table S2](#pone.0042085.s003){ref-type="supplementary-material"}). The sequence data for all 27 *S*. Typhimurium were submitted to the European Read Archive under submission accession number ERA015722 (<http://www.ebi.ac.uk/ena/data/view/ERA015722>) and run accession numbers listed in [Table S3](#pone.0042085.s004){ref-type="supplementary-material"}.

Phylogeny {#s4c}
---------

A maximum likelihood phylogram was generated based on 1159 single nucleotide polymorphism (SNPs) sites across the chromosome using RAxML v7.0.4 [@pone.0042085-Stamatakis1] with GTRGAMMA model of evolution and 100 bootstrap replicates. The phylogram was viewed in FigTree (available at <http://tree.bio.ed.ac.uk/software/figtree/>). The phylogram included the already sequenced and annotated epidemic multidrug resistant strain D23580 EMBL accession number FN424405 and the draft genome of the pre-epidemic and chloramphenicol susceptible *S.* Typhimurium strain A130, accession number ERA000075 [@pone.0042085-Kingsley1]. A130 was isolated from blood in an adult patient in 1997 at QECH, Blantyre, Malawi.

Genome assembly and comparison of plasmid and chromosomal sequences {#s4d}
-------------------------------------------------------------------

Genome assembly was conducted using VelvetOptimiser.pl [@pone.0042085-Zerbino1] to assemble short read sequences and abacas.pl to order the contigs [@pone.0042085-Assefa1].

A file of SNPs identified by mapping using the Burrows-Wheeler Aligner software was opened in the Artemis file of the reference strain SL1344 under comparison to assembled sequences and the annotated strain D23580, to identify any changes in amino acids. Assembled sequences were compared using the Artemis comparison tool (ACT) [@pone.0042085-Carver1] and also uploaded on to SNPSFinder together with the fully-sequenced and annotated *S*. Typhimurium strains LT2 (EMBL accession number AE006468) and D23580 [@pone.0042085-Song1].

Supporting Information {#s5}
======================

###### 

**Similarity of Tn** ***21*** **-like sequence from pSLT-BT to assembled sequences.** Artemis comparison tool generated figures A and B depicting sequence homology of the Tn*21*-like sequence (green feature) from virulence plasmid pSLT-BT to assembled plasmid sequences from the seven strains in the 2006/2008 cluster. Antibiotic resistance genes (*cat*- chloramphenicol, *blaT*- betalactamse, *SulI* and *SulI*- sulphonamide, *dhfrI*- trimethoprim, *aadA*- aminoglycoside and *StrA* and *StrB*- streptomycin) and quartenary ammonium compound resistance gene (*qacE*) are present in all six strains. BLASTN matches are shown as red bands. White spaces are gaps in these draft sequences.
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**Short sequence read mapping to virulence plasmid pSLT-BT sequence.**
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**Mapping to** ***S*** **. Typhimurium SL1344 chromosome and identified single nucleotide polymorphisms.**
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**Accession numbers (** <http://www.ebi.ac.uk/ena/data/view/ERA015722> **).**
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